AstraZeneca has completed the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan, for the global rights to MEDI2070, a biologic candidate being developed for Crohn’s disease. The candidate is an interleukin-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and is ready for Phase II studies for ulcerative colitis, both of which are diseases outside AstraZeneca’s three main therapy areas. As a result, AstraZeneca will not retain a significant ongoing interest in MEDI2070.

Source: AstraZeneca